Cerveau partners with Janssen on PET agent

Radiopharmaceutical developer Cerveau Technologies will collaborate with Janssen Pharmaceuticals on an investigational imaging agent to be used in PET scans.

The agent, F-18 MK-6240, will be used to assess the status and progression of neurofibrillary tangles (NFTs) in the brain. NFTs are made up of aggregated tau protein and are a hallmark of several neurodegenerative diseases, including Alzheimer's disease.

Janssen will use F-18 MK-6240 as a biomarker in research studies to diagnose and evaluate new treatments for neurodegenerative diseases.

Page 1 of 435
Next Page